Furo Hiroko, Whitted Marisa, Lin Tony, Zhou Yi Y, Abdelsayed Sarah, Brimhall Bradley B, Elkin Peter L
Department of Biomedical Informatics, State University of New York (SUNY) at Buffalo, Buffalo, NY, USA.
Department of Family Medicine, State University of New York (SUNY) at Buffalo, Buffalo, NY, USA.
Subst Use. 2024 Jan 20;18:11782218231223673. doi: 10.1177/11782218231223673. eCollection 2024 Jan-Dec.
Reportedly, various urine manipulations can be performed by opioid use disorder (OUD) patients who are on buprenorphine/naloxone medications to disguise their non-compliance to the treatment. One type of manipulation is known as "spiking" adulteration, directly dipping a buprenorphine/naloxone film into urine. Identifying this type of urine manipulation has been the aim of many previous studies. These studies have revealed urine adulterations through inappropriately high levels of "buprenorphine" and "naloxone" and a very small amount of "norbuprenorphine." So, does the small amount of "norbuprenorphine" in the adulterated urine samples result from dipped buprenorphine/naloxone film, or is it a residual metabolite of buprenorphine in the patient's system? This pilot study utilized 12 urine samples from 12 participants, as well as water samples as a control. The samples were subdivided by the dipping area and time, as well as the temperature and concentration of urine samples, and each sublingual generic buprenorphine/naloxone film was dipped directly into the samples. Then, the levels of "buprenorphine," "norbuprenorphine," "naloxone," "buprenorphine-glucuronide" and "norbuprenorphine-glucuronide" were examined by Liquid Chromatography with tandem mass spectrometry (LC-MS/MS). The results of this study showed that high levels of "buprenorphine" and "naloxone" and a small amount of "norbuprenorphine" were detected in both urine and water samples when the buprenorphine/naloxone film was dipped directly into these samples. However, no "buprenorphine-glucuronide" or "norbuprenorphine-glucuronide" were detected in any of the samples. In addition, the area and timing of dipping altered "buprenorphine" and "naloxone" levels, but concentration and temperature did not. This study's findings could help providers interpret their patients' urine drug test results more accurately, which then allows them to monitor patient compliance and help them identify manipulation by examining patient urine test results.
据报道,使用丁丙诺啡/纳洛酮药物治疗的阿片类物质使用障碍(OUD)患者可以对尿液进行各种操作,以掩饰其不遵守治疗的情况。其中一种操作被称为“掺入”掺假,即将丁丙诺啡/纳洛酮薄膜直接浸入尿液中。识别这种尿液操作一直是此前许多研究的目标。这些研究通过“丁丙诺啡”和“纳洛酮”水平异常高以及极少量的“去甲丁丙诺啡”揭示了尿液掺假情况。那么,掺假尿液样本中少量的“去甲丁丙诺啡”是由于浸入的丁丙诺啡/纳洛酮薄膜导致的,还是患者体内丁丙诺啡的残留代谢物呢?这项初步研究使用了来自12名参与者的12份尿液样本以及作为对照的水样。样本根据浸入区域和时间以及尿液样本的温度和浓度进行细分,每片舌下含服的通用型丁丙诺啡/纳洛酮薄膜直接浸入样本中。然后,通过液相色谱-串联质谱法(LC-MS/MS)检测“丁丙诺啡”“去甲丁丙诺啡”“纳洛酮”“丁丙诺啡葡萄糖醛酸苷”和“去甲丁丙诺啡葡萄糖醛酸苷”的水平。这项研究的结果表明,当丁丙诺啡/纳洛酮薄膜直接浸入尿液和水样中时,在两者中均检测到高水平的“丁丙诺啡”和“纳洛酮”以及少量的“去甲丁丙诺啡”。然而,在任何样本中均未检测到“丁丙诺啡葡萄糖醛酸苷”或“去甲丁丙诺啡葡萄糖醛酸苷”。此外,浸入的区域和时间改变了“丁丙诺啡”和“纳洛酮”的水平,但浓度和温度并未产生影响。这项研究的结果可以帮助医疗服务提供者更准确地解读患者的尿液药物检测结果,进而使他们能够监测患者的依从性,并通过检查患者尿液检测结果来帮助识别操作行为。